



(51) International Patent Classification:

A61K 48/00 (2006.01) A61K 31/7105 (2006.01)
A61K 31/7088 (2006.01) C07K 14/725 (2006.01)
C12N 15/115 (2010.01) C12N 15/85 (2006.01)
C12N 15/64 (2006.01) C12N 15/11 (2006.01)

(21) International Application Number:

PCT/US2021/033276

(22) International Filing Date:

19 May 2021 (19.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/027,292 19 May 2020 (19.05.2020) US
PCT/US21/31629 10 May 2021 (10.05.2021) US

(71) Applicant: **ORNA THERAPEUTICS, INC.** [US/US];
450 Kendall Street, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **WESSELHOEFT, Alexander**; c/o Orna Therapeutics, Inc., 450 Kendall Street, Cambridge, Massachusetts 02142 (US). **BARNES, Thomas**; c/o Orna Therapeutics, Inc., 450 Kendall Street, Cambridge, 02142 (US).

GOODMAN, Brian; c/o Orna Therapeutics, Inc., 450 Kendall Street, Cambridge, Massachusetts 02142 (US). **MOTZ, Greg**; c/o Orna Therapeutics, Inc., 450 Kendall Street, Cambridge, Massachusetts 02142 (US). **BECKER, Amy**; c/o Orna Therapeutics, Inc., 450 Kendall Street, Cambridge, Massachusetts 02142 (US). **HORHOTA, Allen T.**; c/o Orna Therapeutics, Inc., 450 Kendall Street, Cambridge, Massachusetts 02142 (US).

(74) Agent: **CAI, Yingying** et al.; Goodwin Procter LLP, 100 Northern Avenue, IP Docketing Dept/7th Floor, Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: CIRCULAR RNA COMPOSITIONS AND METHODS




FIG. 74

(57) Abstract: Circular RNA, along with related compositions and methods are described herein. In some embodiments, the inventive circular RNA comprises group I intron fragments, spacers, an IRES, duplex forming regions, and an expression sequence. In some embodiments, the expression sequence encodes an antigen. In some embodiments, circular RNA of the invention has improved expression, functional stability, immunogenicity, ease of manufacturing, and/or half-life when compared to linear RNA. In some embodiments, inventive methods and constructs result in improved circularization efficiency, splicing efficiency, and/or purity when compared to existing RNA circularization approaches.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*